Your session is about to expire
← Back to Search
Smoking Cessation Agent
Methadone Maintenance Treatment and Smoking Cessation (MMTASC Trial)
Phase 2
Waitlist Available
Research Sponsored by Vancouver Coastal Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
Summary
The main hypotheses guiding the study are: 1. Stable methadone maintenance patients receiving varenicline will be more likely to maintain abstinence than patients receiving placebo 2. There will be no differences in the type and number of symptoms reported between stable methadone maintenance patients receiving varenicline and placebo 3. There will be no changes in methadone dosage between abstinent and non-abstinent smokers 4. There will be no differences in efficacy, withdrawal symptoms, and safety of varenicline between male and female participants
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2022 Phase 4 trial • 39 Patients • NCT0401128050%
Dysgeusia
50%
Anxiety
36%
Sleep Disturbances
29%
Nausea
21%
Agitation
21%
Depression
21%
Headache
14%
Heartburn
14%
Allergies
14%
Cold
14%
Back Pain
7%
Confusion
7%
Aggression
7%
Panic
7%
Stomach Pain
7%
Dizziness
7%
Fatigue
7%
Leg Spasms
7%
Sinusitis
7%
Angina
7%
Increased Blood Pressure
7%
Palpitations
7%
Cellulitis
7%
Rash
7%
Malaise
7%
Weight Gain
7%
Gum Disease
7%
Pharyngitis
7%
Leg Cramps
7%
Muscle Pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Low Dose Varenicline
Standard Dose Varenicline
Awards & Highlights
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 1Experimental Treatment1 Intervention
Group II: placeboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Varenicline
FDA approved
Find a Location
Who is running the clinical trial?
British Columbia Centre of Excellence for Women's HealthUNKNOWN
Vancouver Coastal HealthLead Sponsor
39 Previous Clinical Trials
717,058 Total Patients Enrolled